The long-awaited alternative to Coumadin (warfarin) has just been approved by the United States Food and Drug Administration. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation (afib) for preventing afib-related strokes.
The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa doesn't require the monitoring nor the restrictive diet that warfarin does.
Learn more at:
FDA Approves Pradaxa as Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation